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In the presence of time‐dependent confounding, there are several methods
available to estimate treatment effects. With correctly specified models and
appropriate structural assumptions, any of these methods could provide consis-
tent effect estimates, but with real‐world data, all models will be misspecified
and it is difficult to know if assumptions are violated.
In this paper, we investigate five methods: inverse probability weighting of
marginal structural models, history‐adjusted marginal structural models,
sequential conditional mean models, g‐computation formula, and g‐estimation
of structural nested models. This work is motivated by an investigation of the
effects of treatments in cystic fibrosis using the UK Cystic Fibrosis Registry
data focussing on two outcomes: lung function (continuous outcome) and
annual number of days receiving intravenous antibiotics (count outcome).
We identified five features of this data that may affect the performance of the
methods: misspecification of the causal null, long‐term treatment effects, effect
modification by time‐varying covariates, misspecification of the direction of
causal pathways, and censoring.
In simulation studies, under ideal settings, all five methods provide consistent
estimates of the treatment effect with little difference between methods.
However, all methods performed poorly under some settings, highlighting
the importance of using appropriate methods based on the data available.
Furthermore, with the count outcome, the issue of non‐collapsibility makes
comparison between methods delivering marginal and conditional effects diffi-
cult. In many situations, we would recommend using more than one of the
available methods for analysis, as if the effect estimates are very different, this
would indicate potential issues with the analyses.
KEYWORDS
causal inference, g‐computation formula, g‐estimation, inverse probability weighting, time‐dependent
confounding
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1 | INTRODUCTION
Advanced methods for causal inference in longitudinal observational studies are an important tool for investigating
treatment effects in nontrial settings where the presence of time‐dependent confounders generally precludes the use
of simpler conventional methods. Time‐dependent confounding is an issue in longitudinal studies when a time‐varying
covariate is affected by treatment, but this covariate then also subsequently affects the probability of receiving future
treatment as well as affecting the outcome of interest.1
In these situations, there are a number of methods available to researchers, and one of these methods, in particular,
inverse probability weighting (IPW) of marginal structural models (MSM), has become increasingly popular in applied
research. The increasing use of this method over other methods may in part be due to its relative simplicity, but it is not
clear if other methods may be better suited to some analyses. The methods investigated in this paper are motivated by
questions about the efficacy of long‐term treatment use in cystic fibrosis (CF) and the challenges for addressing these
using longitudinal observational data from a patient registry. In addition to IPW of MSM, we identified four other
methods, which could be used in this setting: history‐adjusted marginal structural models (HA‐MSM), sequential con-
ditional mean models (SCMM), g‐computation formula, and g‐estimation of structural nested models (SNM).
The primary aims of this paper are twofold: (1) to compare the ability and appropriateness of the different analysis
methods for addressing the questions of interest, including to estimate treatment effect modification and to handle
different outcome types and (2) to investigate the robustness of the different methods to handling practical challenges
arising in longitudinal observational data, such as uncertainty about the relative temporality of measures and loss to
follow‐up. In an ideal setting, where we could be sure that all assumptions are met and that all models are correctly
specified, any one of the available methods could be used to obtain consistent treatment effect estimates. However, in
reality, it can be difficult to know if assumptions hold and all models will be misspecified to some degree.
Section 2 of this paper gives more details about the UK CF Registry, the questions we wish to address, and specific
details of the data that present challenges. This is followed in Section 3 by an overview of the five different methods,
which we considered for the analysis of the Registry data. In Section 4, we present simulation studies investigating
the performance of these five methods with two different types of outcomes (normally distributed continuous data
and zero‐inflated negative binomial count data). An analysis of the UK CF registry data is presented in Section 5,
and finally, we discuss the implications of the results of the simulation studies and data analysis in Section 6.
2 | MOTIVATING EXAMPLE
2.1 | CF and the UK Cystic Fibrosis Registry
Cystic fibrosis is the most common life‐threatening inherited disease in white people, and in the UK, there are over
10 000 people living with the disease.2,3 Cystic fibrosis most seriously affects the lungs, where a build‐up in mucus
causes breathing difficulties and leads to an increase in respiratory infections. There are now many treatments available
that can help improve the health of people with CF, but many of these treatments are very time consuming and often
treatments are not stopped once started. This leads to an accumulation of treatments, and treatment burden is a
common complaint among people with CF.4
Almost all treatments currently used in CF care were approved following a successful clinical trial. However, a
limitation of many trials is that they are short in duration, whereas in practice, treatments are used long term. In most
cases, it would not be feasible to run trials for such long periods of times, and it could also be unethical to continue to
withhold treatment from patients if a strong short‐term benefit has been observed.
The UK CF Registry is a national database, which has collected annual data on almost all people with CF in the UK
since 2007. At an annual assessment, detailed information is obtained on many different measures of health status as
well as all the treatments received in the past year.5
This paper will focus on one common CF treatment, dornase alfa (DNase), which was licensed for use in the UK in
1994 after a randomised trial showed efficacy at improving lung function over a 6‐month period.6 Subsequent studies
have investigated the effects of up to 2 years' use of DNase, but in practice, patients generally continue to receive DNase
indefinitely once treatment has been started.7
To illustrate the potential of the statistical methods with different types of outcomes, this paper will consider the
effects of treatment on two important clinical outcomes: percent predicted forced expiratory volume in 1 second
(ppFEV1) (a continuous outcome measuring an individual's lung function) and annual number of days of intravenous
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antibiotic therapy (IV days) (a count outcome of the number of days an individual received intravenous antibiotics in a
given year). The decision to start prescribing DNase to a patient depends on many factors, including pretreatment mea-
sures of ppFEV1 and annual IV days, which are then in turn potentially affected by treatment use.
Figure 1 shows a directed acyclic graph (DAG) of the assumed causal pathways between key variables in the UK CF
Registry. Data are obtained at annual visits. Treatment status at visit t is denoted Xt, Ft denotes ppFEV1, and Vt denotes
IV days. We focus on patients not using treatment at a baseline visit 0, X0 = 0. At subsequent annual visits, their ppFEV1
on that day is recorded, and data about the previous year are also collected, such as which treatments they received
throughout the year and their total number of IV days.
The DAG visualises ppFEV1 at visit t−1 affecting treatment at visit t, annual IV days at visit t affecting treatment at
visit t, DNase use at visit t affecting all future measures of ppFEV1 and annual IV days, and direct longitudinal associ-
ations between ppFEV1 and annual IV days. There may also be other important baseline or time‐varying confounders,
which have not been included in the DAG for clarity. In this paper, we focus on investigating the effect of treatment on
lung function and IV days and how this effect might change with continued use of treatment over several years.
2.2 | Features and challenges in the analysis of this data
As is common with most observational data, there are a number of issues that need to be considered when approaching
the analysis of the UK CF Registry data.
One challenge is the use of the available methods with different types of outcomes. One of our outcomes of interest,
ppFEV1, is continuous and can be approximated by a conditionally normal distribution. All of the methods described in
this paper can easily accommodate such an outcome. However, the other outcome, annual IV days, is a count outcome
ranging from 0 to 365, which we model with a zero‐inflated negative binomial distribution. This can be harder to
incorporate into some of the methods, and we will discuss these issues in Section 3.7.
In addition to considering two different types of outcome, we have identified 5 key features of the analysis of the UK
CF registry. The first three of these question the ability and appropriateness of the different analysis methods for esti-
mating the treatment effect: whether there exists any treatment effect at all, whether there are only short‐term or also
long‐term effects, and whether there is effect modification of the treatment effect by time‐varying covariates. The second
category are challenges that may arise because of the nature of the data available to investigate the above questions.
Here, we consider the issues of censoring and uncertainty of the direction of causal pathways between variables.
The following subsections give further details on each of these five issues.
2.2.1 | Causal null hypothesis
The DAG shown in Figure 1 shows a causal effect of treatment on the outcomes of interest. To date, randomised trials
have demonstrated the efficacy of DNase treatment in improving ppFEV1, but no studies have yet shown a significant
effect of the treatment on reducing the rate of IV days. Furthermore, in a nontrial setting, where, for example,
adherence levels may not be as high as in clinical trials, the findings of a causal effect of treatment may not be
replicated. For this reason, methods that benefit from a degree of robustness to model misspecification at the causal null
would be attractive.
FIGURE 1 Directed acyclic graph of causal pathways between treatment (Xt), ppFEV1 (Ft), and IV days (Vt). Baseline and other time‐
varying confounders are not shown for clarity
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2.2.2 | Long‐term treatment effects
We define a long‐term treatment effect as an effect of Xt on Ys (s > t) not mediated via intermediate treatments. No
studies have previously looked at the effects of DNase beyond 2 years, and it therefore remains unknown how the effect
of treatment might change with length of use. Taking the example of ppFEV1, two possible ways in which the treatment
may affect the outcome are (1) the ppFEV1 trajectories of those receiving and not receiving treatment continue to grow
apart indefinitely through time or (2) after the initial increase in ppFEV1 that has been observed at the start of taking
treatment, the effectiveness of treatment may decrease with the two counterfactual trajectories no longer diverging.
These two hypothetical lung function trajectories compared with the trajectory when not receiving treatment are shown
in Figure 2. As it is unknown how the effect of treatment might change through time, it is important that the methods
are flexible enough to identify the true long‐term effects.
2.2.3 | Effect modification by time‐varying covariates
We hypothesise that the effect of treatment may depend on the previous levels of ppFEV1 and number of IV days. This is
because if a person starts treatment when they already have a healthy ppFEV1 level, it is unlikely that treatment could
further improve ppFEV1, whereas it is realistic that the treatment could be much more effective in an individual with an
lower ppFEV1. For informing practice, rather than just identifying the population average effect of treatment, it is
important to gain understanding of how the effect of treatment might change depending on other covariates, and for
this reason, it would be preferable to use a method that can test for the presence and estimate the strength of any effect
modification.
2.2.4 | Misspecification of the direction of causal pathways
The DAG in Figure 1 includes assumptions about the direction of the causal pathways. For some variables, the appro-
priate direction of the causal pathway is clear (eg, the pathway from total IV days in 1 year to ppFEV1 measured at the
end of the year). However, for other pathways, the appropriate direction for the arrow is less clear.
The direction of the causal pathway between treatment and number of IV days is particularly challenging. Both
variables are summaries of the previous year, and some individuals may have had lots of IV days at the start of the year,
which prompted them to start treatment, whereas others may have started treatment earlier, but then had IV days later
in the year. In reality, therefore, the causal pathway between Xt and Vt is likely to go both ways, but in many methods, it
will be necessary to specify just one direction for this pathway.
We have decided to focus on investigating the effect of Xt on Vt+1, as, due to temporality, this pathway can only be
directed this way, and to treat Vt as a confounder of this effect. In the real Registry data, we cannot know whether this is
misspecified or not, and therefore, it is important to understand the potential extent of the bias in treatment effect
estimates under different methods when the direction of this pathway has been misspecified.
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FIGURE 2 Two possible trajectories of lung function with long‐term dornase alfa treatment [Colour figure can be viewed at
wileyonlinelibrary.com]
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2.2.5 | Censoring
We are fortunate that there are very few people lost to follow‐up in the UK CF Registry, and each year, there are
relatively few deaths compared with the total number of people in the Registry. Nevertheless, it is possible that
the fact that some individuals are censored for either of these reasons may bias the results. Therefore, we also wish
to investigate how the different methods handle censoring. Although in reality there would likely be different pro-
cesses affecting the probability that an individual dies or is lost to follow‐up, in this paper, we only consider one
missing at random scenario where an individual's probability of being censored depends on previously measured
variables.
3 | METHODS
3.1 | Notation and assumptions
We discuss the statistical methods with generic notation. Consider a cohort followed up annually from visit t=0 up to
visit t=T. The treatment received at time t is denoted Xt, and each year, a person can receive (Xt=1) or not receive
(Xt=0) treatment during the period since the last visit. The outcome of interest, Yt, is also measured annually. We
assume that at each visit, Xt precedes Yt and define a 1‐year treatment effect to be the effect of Xt on Yt. We also have
baseline confounders, B, and time‐varying confounders, C.
Xt is a vector of the treatment history for an individual from visit 0 up to and including visit t, and we use the coun-
terfactual notation Y xt¼1t to refer to the outcome that would have been observed at visit t if an individual had received
treatment up to and including visit t.
For all methods, we make the following four assumptions: no interference, positivity, consistency, and no unmea-
sured confounding. No interference means that for a given individual, their counterfactual outcome Y xt is not affected
by the treatment that another individual receives.8 Positivity means that all individuals had a conditional probability
strictly greater than 0 and strictly less than 1 of receiving treatment at all visits given their history,
0 < PðXt ¼ 1jXt−1; Yt−1; Ct;BÞ< 1.9 Consistency means that for each individual, the counterfactual outcome under
the observed treatment is equal to the observed outcome,Yi ¼ Yxii when xi ¼ Xi.10 Finally, no unmeasured confounding
means that conditional on the past observed variables the treatment received at visit t is independent of the counterfac-
tual outcome, Y xtt ⫫ XtjXt−1; Yt−1; Ct;B. 1
The following subsections give an overview of the methods that are considered for the analysis of the UK CF
Registry. We introduce the methods with a continuous outcome in mind. Referring back to our motivating example
and the DAG in Figure 1, we can consider ppFEV1(Ft) to be the outcome of interest with IV days (Vt) acting as a
time‐dependent confounder. The count variable of IV days is also of interest as an outcome, and in Section 3.7, we
outline how the methods can be extended for use with a count outcome.
3.2 | IPW of marginal structural models
Inverse probability weighting of MSM11 has become an increasingly popular method to deal with time‐dependent con-
founding. We consider MSM of the following form:
E Y xtt
  ¼ β0 þ ∑
t
i¼1
βxi xi; (1)
where the βx1 to βxt represent separate effects for treatment at each visit, thereby allowing for long‐term treatment
effects. However, due to confounding, directly using the observed values and calculating E½YtjXt ¼ xt does not equate
to the counterfactual E½Y xtt .
Inverse probability weighting of the observations enables consistent estimation from an MSM by reweighting obser-
vations so that the levels of confounding variables become equally balanced between treated and untreated individuals.
This is achieved by assigning large weights to individuals who were estimated to be unlikely to receive the treatment
they actually received and downweighting observations for which there are lots of observations estimated to have
similar propensities to receive the same treatment history.
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To calculate the weights, one first estimates the propensity score, which is the probability of receiving treatment at
each visit:
P Xt ¼ 1jXt−1; Yt−1; Ct;Bð Þ ¼ expit β0 þ βXXt−1 þ βYY t−1 þ βCCt þ βBBð Þ: (2)
Then this model is used to calculate the estimated probability that each person received the treatment they actually
received, ie, for those who did receive treatment, we use the estimated probability from the above model and for those
who did not receive treatment, 1 minus the estimated probability. The probability of their treatment history is then the
product of these estimated probabilities from visit 1 up to visit t.
The inverse of the estimated probabilities can be used directly as the weights, but it is usually preferable to use so‐
called stabilised weights1 where the numerator of the weights is the probability of receiving treatment based on previous
treatment history and baseline covariates only,
SWt ¼ P
XtjXt−1;Bð Þ
P XtjXt−1; Yt−1; Ct;Bð Þ ¼∏
t
i¼1
P XijXi−1;Bð Þ
P XijXi−1; Yi−1; Ci;Bð Þ: (3)
A final MSM, such as that given in Equation 1, can then be fit where the observations are weighted using the
estimated weights. However, note that any baseline confounders included in the numerator of Equation 3 must also
be included in the MSM. This would result in a conditional estimate, meaning if a marginal estimate is desired then
no confounders should be included in the numerator.
Due to the fact that time‐varying covariates are not included in the MSM, this method does not allow for the
estimation of effect modification by time‐varying covariates. However, the method also does not need the assumption
that there is no effect modification and will estimate consistent population average effects even if the effect of treatment
is not uniform for the whole population.
Using stabilised weights helps to reduce the variability in the weights, but in cases where there are strong time‐vary-
ing predictors of treatment, the weights can remain highly variable that can lead to instability. Therefore, it can some-
times be preferable to truncate the most extreme weights, even though this may introduce some bias.12,13 In this paper,
we will present the results of IPW analyses with and without truncation of the stabilised weights to the 1st and 99th
percentile.
In the presence of censoring, it is also possible to incorporate censoring weights into the analysis. Similarly to the
previously described weights, we weight individuals with stabilised inverse weights of their estimated probability of
being censored before visit t,
LTFUWt ¼∏
t
i¼1
P LTFUið Þ
P LTFUijXi−1; Yi−1; Ci−1;Bð Þ: (4)
Using this method, we assume that future visits are missing at random, ie, censoring is affected by previously
measured variables. The estimated censoring weights can then be multiplied by the estimated stabilised weights to give
the weights to be used to account for bias due to both confounding and censoring.
3.3 | History‐adjusted marginal structural models
As stated in the previous section, one limitation of IPW of MSM is that effect modification of the treatment effect by
time‐varying covariates cannot be estimated. Therefore, in cases where the estimation of an interaction term is desired,
HA‐MSM are an extension to IPW of MSM, which do allow for this.14
In the standard MSM described in the Section 3.2, observations are reweighted based on all covariates measured
after baseline until the visit of the outcome of interest. In an HA‐MSM, the reweighting is done separately from each
time of treatment t up to the time of outcome, s (t ≤ s). Covariates measured prior to the treatment at time t can be
included in the final HA‐MSM in the same way as baseline covariates were included in the standard MSM.
Formally, the stabilised weights for exposure at time t on outcome at time s are given by
SWts ¼∏
s
i¼t
P XijXi−1;Bð Þ
P XijXi−1; Yi−1; Ci;Bð Þ; (5)
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and an example of the HA‐MSM could be given by
E Y xss jxt−1;yt−1; ct; b
  ¼ β0 þ βbbþ βcct þ βx xt−1 þ βyyt−1 þ∑
s
i¼t
βxi xi þ∑
s
i¼t
βinti xi yt−1: (6)
In Equation 6, we have included an interaction term between previous measures of the outcome (itself a time‐vary-
ing confounder) and treatment so as to allow the estimation of any effect modification.
As with IPW of MSM, it is also possible to estimate censoring weights, in this case estimating an individual's
probability of being censored between visits t and s and multiplying these weights with the stabilised weights.
3.4 | Sequential conditional mean models
Even in the presence of time‐dependent confounding, it is still possible to use standard regression methods, but these
methods can only estimate total effects.15 The total effect of a treatment, Xt, on an outcome Ys (s> t) would include
not only the direct effect of Xt on Ys and the indirect effects of Xt on Ys through time‐varying covariates but also the
indirect effect of Xt on Ys mediated through future exposures. It cannot, therefore, be used to investigate the effect of
receiving 2 years' treatment in our example, as some people discontinue treatment. For this reason, in the examples
here, this method is only used to estimate “short‐term” effects, which we define as the effect of 1‐year treatment on
the outcome measured at the end of the year.
These SCMM will give a consistent estimate of the 1‐year effect of treatment as long as we appropriately control for
all confounding effects of this short‐term effect. For example, the following short‐term model would suffice if the most
recent measures of all covariates were sufficient to remove confounding:
E YtjXt; Yt−1; Ct;Bð Þ ¼ β0 þ βX1Xt þ βX2 Xt−1 þ βY Y t−1 þ βCCt þ βBB: (7)
It is also possible to incorporate propensity scores into the SCMM to provide a doubly robust estimator. The propen-
sity score can be calculated as it was in the IPW method by using Equation 2, and this is then incorporated into the
SCMM as follows:
E YtjXt; Yt−1; Ct;B; ptð Þ ¼ β0 þ βX1Xt þ βX2Xt−1 þ βYY t−1 þ βCCt þ βBBþ βppt: (8)
Although this method cannot provide estimates for the effects of varying lengths of treatment duration, the simplic-
ity of the method is appealing, and these short‐term effect estimates can also be compared with the 1‐year treatment
effect estimates from the other methods. SCMM also form the first step of the next 2 methods: g‐computation formula
and g‐estimation of SNM.
3.5 | G‐computation formula
The g‐computation formula first described by Robins16 is another method that can deal with the issue of time‐dependent
confounding to give consistent estimates of long‐term treatment effects. In this method, short‐term models, ie, models for
1‐year time effects, for all time‐varying covariates (in our example, Y and C) are used to simulate counterfactual outcomes
under different treatment trajectories sequentially through time.
For example, the time‐varying continuous outcome Y could be modelled by Equation 7 and counterfactuals for Y1
could then be simulated setting everyone either receiving or not receiving treatment at visit 1:
~Yx1¼11 ¼ β^0 þ β^YY 0 þ β^CC1 þ β^BBþ β^X1 þ ~ε; (9)
~Yx1¼01 ¼ β^0 þ β^YY 0 þ β^CC1 þ β^BBþ ~ε; (10)
where ~ε is a random draw from a normal distribution whose standard deviation is the model‐estimated root mean
square error, resulting in simulated counterfactual measures.
Similar short‐term models would need to be specified for all time‐varying covariates C to allow the counterfactuals
for all covariates to be simulated at visit 1. In our example, we have one time‐varying confounder, which follows a zero‐
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inflated negative binomial distribution. Therefore, this was used to model the data and then to simulate random draws
for the count for each individual.
The process can then be repeated sequentially for all visits. For example, at visit 2, there would be four counterfac-
tuals simulated for each individual, corresponding to (1) receiving treatment at both visits, (2) at the first visit only, (3) at
the second visit only, or (4) never receiving treatment. These counterfactuals could be simulated, respectively, as follows:
~Y x1¼1;x2¼12 ¼ β^0 þ β^Y ~Yx1¼11 þ β^C ~Cx1¼12 þ β^BBþ β^X1 þ β^X2 þ ~ε; (11)
~Y x1¼1;x2¼02 ¼ β^0 þ β^Y ~Yx1¼11 þ β^C~Cx1¼12 þ β^BBþ β^X2 þ ~ε; (12)
~Y x1¼0;x2¼12 ¼ β^0 þ β^Y ~Yx1¼01 þ β^C ~Cx1¼02 þ β^BBþ β^X1 þ ~ε; (13)
~Y x1¼0;x2¼02 ¼ β^0 þ β^Y ~Yx1¼01 þ β^C~Cx1¼02 þ β^BBþ ~ε: (14)
The counterfactual outcomes under different treatment trajectories can then be compared with a MSM, eg,
E Y xtt
  ¼ β0 þ ∑
t
i¼1
βxixi: (15)
One well‐known drawback of the use of this method with non‐linear models is the g‐null paradox.16,17 This is an
issue whereby given a large enough sample size, the causal null hypothesis will always be rejected even if there is in
fact no treatment effect. This is due to the fact that the combination of different parametric models will be inconsistent
with the null hypothesis.
3.6 | G‐estimation of structural nested models
The final method we will consider is g‐estimation of SNM.18 This method has been used less than the previously
described methods, and this may partly be due to the perceived difficulty of applying the method with standard statis-
tical software.19 However, a recent paper by Vansteelandt and Sjolander revisits g‐estimation, showing how it can be
implemented with standard software.20
Similar to HA‐MSM, this method can estimate the effect of all treatments at visits t on outcomes at visits s where t≤s.
Starting from the short‐term model as in the SCMM, we obtain an estimate for the 1‐year effect of treatment, βX1 ,
E YtjXt; Yt−1; Ct;B; ptð Þ ¼ β0 þ β1Xt−1 þ β2Yt−1 þ β3Ct þ β4Bþ β5pt þ βX1Xt; (16)
where pt is the estimated propensity score.
The estimate βX1 can then be used to construct counterfactuals by subtracting the estimated 1‐year effect to be able
to see if there is any extra effect for additional years of treatment,
Hst ¼ Ys− ∑
s
u¼tþ1
βXs−uþ1Xu: (17)
It can be seen that in the case where t = s, Hst is simply equal to Ys as expected, whereas intermediate treatment
effects are subtracted if t< s. In the first iteration, as we only have an estimate for βX1 , we can only calculate Hst where
s ≤ t+1. However, this now allows us to estimate both the 1‐year and 2‐year effects with the following model:
E HsjjXj; Yj−1; Cj;B; pj
 
¼ β0 þ β1Xj−1 þ β2Yj−1 þ β3Cj þ β4Bþ β5pj þ βXs− jþ1Xj: (18)
Iteration of Equations 17 and 18 allows the estimation of all βXs− jþ1 where 1 ≤ j ≤ s and 1 ≤ s ≤ T.
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Similarly to HA‐MSM, g‐estimation is a method that allows the estimation of effect modification by time‐varying
covariates by including interaction terms in both Equations 17 and 18.
Censoring weights as described in Section 3.3 can also be incorporated into g‐estimation, weighting individuals by
their estimated probability of being censored between visits t and s.
3.7 | Use of methods with a count outcome
For our motivating example, we have 2 outcomes of interest, ppFEV1 and annual IV days. The first of these is a contin-
uous outcome, and all 5 of the methods can easily handle this outcome. More care is needed when considering annual
IV days, which is a count outcome ranging from 0 to 365.
Upon investigation, IV days can be considered approximately distributed by a zero‐inflated negative binomial distri-
bution. Modelling this outcome therefore requires two separate estimation procedures: (1) logistic regression to estimate
the odds of a count of zero IV days and (2) negative binomial regression to estimate the rate of IV days. Therefore, there
are two separate parts to the treatment effect: the estimated effect of treatment on having zero IV days (an odds ratio)
and the estimated effect of treatment on the number of IV days (a rate ratio).
For SCMM, this is not an issue, as one can simply fit a zero‐inflated negative binomial model to estimate both
effects. Similarly, IPW, HA‐MSM, and g‐computation formula can all handle different types of outcome by just changing
the final MSM, eg,
E Y xtt
  ¼ expit β0 þ ∑
t
i¼1
βxixi
 
exp γ0 þ ∑
t
i¼1
γxixi
 
: (19)
Unlike the other 4 methods, which can easily handle different types of outcome, the method of g‐estimation
described in Section 3.6 has until recently only been described for continuous outcomes. However, a recent paper has
shown how this method can be adapted to allow for a count outcome by modelling with a gamma distribution.21 This
allows for the estimation of the effect of treatment on the rate of IV days, but would still not allow for the decomposition
of the effect into the probability of a zero count and a rate, as the other methods do.
Another issue one needs to consider when modelling a count outcome is non‐collapsibility. Unlike with the contin-
uous outcome where, thanks to collapsibility, the marginal and conditional effects are the same, this no longer holds for
models suitable for count outcomes. Thus, the treatment effect on IV days will differ between methods depending on
whether the method delivers a marginal effect (IPW and g‐computation formula) or a conditional effect (SCMM,
HA‐MSM and g‐estimation).
3.8 | Overview of methods
Referring back to the five features of the UK CF Registry introduced in Sections 2.2.1 to 2.2.5, we would hope for any
method to estimate no treatment effect on average when there is no treatment effect, but the g‐null paradox may mean
that the g‐computation formula could perform poorly in this setting.
Except for SCMM, all methods can estimate long‐term treatment effects, and in all our analyses, we will include
separate terms for treatment at each visit making no assumptions about a continuous effect or a trend effect. SCMM will
only be used to estimate the short‐term treatment effect, but the method will consistently estimate this even if there are
longer term effects.15
In terms of effect modification, three of the methods (SCMM, g‐estimation, and HA‐MSM) allow interaction
terms, meaning that when this is of interest, only these methods can be used. IPW of MSM and g‐computation formula
can still be used to estimate population average effects even in the presence of effect modification by time‐varying covar-
iates, whereas the other three methods may show bias in estimating population average effects if there is in fact effect
modification and it is not explicitly modelled.
When there is censoring, three of the methods (IPW of MSM, HA‐MSM, and g‐estimation) can use censoring
weights to correct for the individuals who do not have full follow‐up. Censoring should not affect the short‐term models
used in SCMM, and similarly, the g‐computation formula uses the same short‐term models and then simulates follow‐
up without censoring.
With the exception of SCMM, it is normally advised to use a bootstrap procedure to obtain standard errors (SE). This
is because all the methods contain a number of steps of estimation and just using the final model‐based SE would fail to
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account for the uncertainty from the earlier steps.13,14,22,23 The bootstrap provides valid results as all of these methods
produce regular estimators.24
4 | SIMULATION STUDIES
The following section gives details of simulation studies that were performed to investigate how the features and
challenges identified in Section 2.2 (robustness to misspecification of the causal null, long‐term treatment effects, effect
modification by time‐varying covariates, misspecification of the direction of causal pathways, and censoring) affect the
performance of the five methods given in Section 3 (SCMM, IPW of MSM, HA‐MSM, g‐computation formula, and g‐esti-
mation of SNM).
The aims of the simulation studies are to understand how the performance of the analysis methods might be affected
by these challenges and to help provide a framework for the best analysis strategy for the real UK CF Registry data. The
simulation studies were performed following the guidelines given by Burton et al25 and full details of the design of the
simulation studies can be found in Supporting Information, with a summary below.
4.1 | Design of simulation studies
Datasets were simulated for six different scenarios as shown in Figure 3. In each DAG, the arrows highlighted in red
show the specific differences compared with the other scenarios.
The first scenario is the standard scenario, which will be the baseline with which to compare the other methods. In
this scenario, there is a 1‐year treatment effect, there are no direct long‐term effects, although there are long‐term effects
mediated through other time‐varying covariates. This is the scenario for which all the methods will be correctly speci-
fied and as such we would expect all methods to provide consistent estimates for the treatment effects in this scenario.
In the second scenario, we simulate without any treatment effect, and the third scenario adds long‐term direct
effects of treatment. In this case, the long‐term direct effects are actually negative effects, slightly counteracting the
beneficial 1‐year effects, resulting in a decrease in the treatment effect through time.
The fourth scenario simulates effect modification of treatment by time‐varying covariates. Although effect modifica-
tion is generally not shown in DAGs, we have included arrows in Figure 3 to help illustrate how the presence of effect
modification would change the treatment effect.
FIGURE 3 Simplified directed acyclic graphs showing data generation process for each of the 6 scenarios investigated. The real data were
generated for up to 5 visits, and there is additionally a baseline confounder, age, affecting all variables
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The fifth scenario concerns the direction of the causal pathway between treatment and IV days in the same year. In
our analysis, we will always analyse the data as if the direction of the causal pathway is from Vt to Xt, even when the
data have actually been simulated the other way around, ie, Xt affects Vt.
In the final scenario, individuals can either all be followed up for 5 visits, or there can be some censoring, whereby
“unhealthy” individuals are more likely to be censored at an earlier visit. This corresponds to a missing at random sce-
nario, whereby the probability of being censored depends on observed variables.
For each scenario, we simulated 1000 datasets, each with 7500 individuals. The data were generated so as to imitate
the observed data in the Registry as closely as possible. In the real data, there are many treatments that individuals
could be receiving and also many covariates that might be confounders. For the simulation studies, we kept just one
binary treatment, Xt, and the 2 outcome variables, ppFEV1(Ft) and annual IV days (Vt), which also act as time‐depen-
dent confounders. Lung function was simulated as a continuous variable with a normal distribution and IV days as a
count outcome following a zero‐inflated negative binomial distribution. In addition to these 3 variables, we also gener-
ated age from a beta distribution corresponding to what was observed in the real data to act as a baseline confounder.
For each method and each scenario, we run two analyses: the first considering ppFEV1 as the outcome and the sec-
ond annual IV days as the outcome. For each simulation, the coefficients corresponding to the treatment effects will be
stored. For SCMM, which can only measure short‐term effects, only the coefficient corresponding to 1 year of treatment
will be stored. For all other methods, we estimate the effects of up to 5 years' treatment use on ppFEV1 and up to 4 years'
treatment use on IV days. The reason for this difference is due to the 1‐year effect of treatment on lung function being
defined as Xt→Ft, whereas the 1‐year effect of treatment on IV days is Xt→Vtþ1. As such, there is always one extra year
of data available for the lung function outcome.
We will compare the methods based on the bias, empirical SE, and mean squared error (MSE). Although it is known
that the model‐based SE are biased for most of these methods, we will also store the estimated robust SE so as to
compare them to the empirical SE.
4.2 | Results of simulation studies
4.2.1 | Continuous outcome
In Figure 4, we present kernel density plots showing the results of the simulation studies for the normally distributed
continuous outcome. We only present results for the 1‐year effect and the 5‐year effect to show the 2 extremes of short‐
to long‐term effects. In all cases, the results for the 2‐ to 4‐year effects followed the trend between the 1‐year and 5‐year
effects. More details of the results can be found in Table S3.
As expected, all 5 methods to provide consistent estimates for the “standard” scenario where all the models are cor-
rectly specified. The only method that performs poorly here is using truncation with IPW, but this is also to be expected
as it is known that due to truncation the weights would no longer fully account for confounding. The 5‐year treatment
effect estimates are slightly biased, but when using a much larger sample size, all methods were unbiased; therefore, we
believe this residual bias is due to the sample size, which we have kept at 7500 individuals as it is unlikely that we would
ever obtain a larger sample from the UK CF Registry.
These findings are repeated for the scenarios where there is no treatment effect, where the treatment effect
decreases over time, and where there is censoring (provided that censoring weights are used for IPW, HA‐MSM, and
g‐estimation).
For the scenario where the causal pathway between a confounder and treatment is specified the wrong way round,
we find that the situation is the opposite: All methods are biased, but IPW and HA‐MSM perform comparatively well
when the weights are truncated. However, untruncated, they perform very poorly with very large variability and even
fail to converge on an estimate many times.
When considering effect modification by time‐varying covariates, all the methods can still be used to provide an estimate
for the population‐average effect. For the 1‐year effects, all the methods provided consistent estimates; however, at 5 years,
there was some noticeable bias for g‐estimation and HA‐MSM. These are the 2 methods that can incorporate the estimation
of effect modification by time‐varying covariates, and not including these interactions terms when they are in fact present
has introduced bias. Conversely, although IPW and g‐computation formula cannot estimate interaction terms, they do
not assume that there is no effect modification and can provide consistent estimates for the population‐average effect.
If the aim is to estimate the strength of any effect modification by time‐varying covariates, then it would be neces-
sary to use HA‐MSM, SCMM, or g‐estimation, and these results are presented in Figure 5 (and Table S4). We see that all
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3 methods perform similarly well in estimating interaction terms, although there is still some finite sample size bias,
and a much larger sample size would be needed to accurately estimate the interaction terms. Even in cases where there
is no effect modification, including an interaction term in the models did not introduce bias, and the methods correctly
estimate zero for the interaction term on average.
3 3.5 4 4.5
1 Year Effect
Standard Scenario
16 18 20 22
5 Year Effect
−1 −.5 0 .5 1
IPW
IPW (truncated)
HA−MSM
HA−MSM (truncated)
SCMM
G−Formula
G−Estimation
1 Year Effect
No Effect Scenario
−4 −2 0 2 4
5 Year Effect
2.5 3 3.5 4
1 Year Effect
Decreasing Effect Scenario
8 10 12 14 16
5 Year Effect
1 1.5 2 2.5 3
1 Year Effect
Effect Modification Scenario
6 8 10 12
5 Year Effect
3 4 5 6
1 Year Effect
Reversed Causal Pathway Scenario
16 18 20 22
5 Year Effect
3 3.5 4 4.5 5
1 Year Effect
Censoring Scenario
13 15 17 19 21 23 25
5 Year Effect
Effect Estimates for Continuous Outcome
FIGURE 4 Kernel density plots showing the distribution of population‐average effect estimates for a continuous outcome. The vertical line
shows the correct effect. HA‐MSM, history‐adjusted marginal structural models; IPW, inverse probability weighting; SCMM, sequential
conditional mean models
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When considering the SE, only in SCMM and HA‐MSM did the model‐estimated SE approximate the empirical SE.
This is theoretically known in the case of SCMM with the propensity score known and, therefore, will be approximately
correct when the propensity score is well estimated. In the case of HA‐MSM, we believe this to be a peculiarity of our
simulation setting, and it is unlikely to be true generally. For this reason, for all methods other than SCMM, a bootstrap
procedure should be used to obtain reliable SE estimates. Comparing the methods, g‐computation formula consistently
shows the smallest empirical SE, followed by SCMM, g‐estimation, and HA‐MSM with similar SE and, finally, IPW with
the largest SE. In the scenario of reversed causal pathways, IPW and HA‐MSM had especially large SE when
untruncated weights were used.
4.2.2 | Count outcome
Unlike with the continuous outcome, due to the issue of non‐collapsibility, we do not compare the effect estimates for
the count outcome to a “correct” value. However, Figures 6 and 7 present the effect estimates and SE for both the odds
of a zero count and the rate of the count. As with the continuous outcome, more detailed results can be found in
Table S5.
Both IPW and g‐computation formula provide marginal effect estimates and in almost all cases provide very similar
estimates. The only setting where they do not provide similar estimates is the case of reversed causal pathways where
IPW performs very poorly with very large variability, as was also seen for the continuous outcome.
Considering the 3 methods that provide conditional effect estimates, we note that the methods are not in general
in agreement, and this is due to the fact that the final models condition on different subsets of variables. In the case
of g‐estimation, due to the fact that the method can only estimate a rate (rather than also accounting for the separate
process of excess zeroes), the estimates from this method are generally very different from all other methods.
The only case where all 5 methods are in agreement is when there is no treatment effect. Here, both the marginal and
conditional effect estimates are zero. This suggests that any method could be used to perform a test of the null hypothesis
of no treatment effect, but the strength of any effect estimates cannot directly be compared between methods.
The results for estimating interaction terms are presented in Figures 8 and 9 (Table S6). The findings are similar to
the case of interaction terms with continuous outcomes, except for the case of g‐estimation where even in the case
−.3 −.2 −.1 0 .1 .2 .3
1 Year Effect
No Effect Scenario
−1 −.5 0 .5 1
5 Year Effect
−.3 −.2 −.1 0 .1 .2
HA−MSM
HA−MSM (truncated)
SCMM
G−Estimation
1 Year Effect
Standard Scenario (No Effect Modification)
−1.5 −1 −.5 0 .5
5 Year Effect
−1 −.9 −.8 −.7 −.6 −.5
1 Year Effect
Effect Modification Scenario
−4.5 −4 −3.5 −3 −2.5 −2
5 Year Effect
Interaction Effect Estimates for Continuous Outcome
FIGURE 5 Kernel density plots showing the distribution of interaction effect estimates for a continuous outcome. The vertical line shows
the correct effect. HA‐MSM, history‐adjusted marginal structural models; IPW, inverse probability weighting; SCMM, sequential conditional
mean models
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where there is no effect modification in the data generation process, the method did not average on no effect modifica-
tion. This is again due to non‐collapsibility, where although there is no effect modification present when assuming the
data follow a zero‐inflated negative binomial distribution, there may be under different distributional models.
Similar to continuous outcomes, the model estimated SE from HA‐MSM and SCMM approximated the empirical SE
well, but again, we would recommend a bootstrap procedure to be used for all methods other than SCMM.
1 1.2 1.4 1.6 1.8 2 2.2
1 Year Effect
Standard Scenario
2.8 3.2 3.6 4 4.4
4 Year Effect
−.1 0 .1
IPW
IPW (truncated)
HA−MSM
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4 Year Effect
1 1.5 2 2.5
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4 Year Effect
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FIGURE 6 Kernel density plots showing the distribution of population‐average effect estimates for the odds of a zero count. HA‐MSM,
history‐adjusted marginal structural models; IPW, inverse probability weighting; SCMM, sequential conditional mean models
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5 | DATA ANALYSIS
Based on the findings from the simulation studies, if the real causal pathways in the Registry data are similar to those
used in the simulation studies, all 5 available statistical methods would be suitable to investigate the effects of DNase on
ppFEV1 and annual number of IV days.
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FIGURE 7 Kernel density plots showing the distribution of population‐average effect estimates for the rate of a count outcome. HA‐MSM,
history‐adjusted marginal structural models; IPW, inverse probability weighting; SCMM, sequential conditional mean models
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FIGURE 8 Kernel density plots showing the distribution of interaction effect estimates for the odds of a zero count. HA‐MSM, history‐
adjusted marginal structural models; SCMM, sequential conditional mean models
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FIGURE 9 Kernel density plots showing the distribution of interaction effect estimates for the rate of a count outcome. HA‐MSM, history‐
adjusted marginal structural models; SCMM, sequential conditional mean models
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Unfortunately, the key challenge identified in the simulation studies was that misspecifying the direction of a causal
pathway will introduce bias no matter which method is used. In the Registry data, it is likely that the real direction of
the causal pathway between treatment (Xt) and annual IV days (Vt) is somewhere between the two extremes of the best‐
case scenario where Xt is only affected by Vt and the worse‐case scenario where Xt only affects Vt. In this setting, the
simulation studies showed that we might expect IPW and HA‐MSM to perform particularly poorly if the extreme
weights are not truncated. Nevertheless, we still perform the analysis here both with and without truncation to compare
the effect of truncating weights.
For these analyses, we must also consider the four assumptions highlighted in Section 3.1: no interference, positivity,
consistency, and no unmeasured confounding. Interference should not be an issue, because CF is a non‐infectious
condition. Furthermore, people with CF are generally kept out of direct contact with one another to avoid cross‐infec-
tion of respiratory microorganisms.4 The assumption of positivity was also considered to be valid for this investigation.
Although guidelines do exist to help advise when patients might benefit from DNase, it is not uncommon for patients to
receive or not receive treatment despite the guidelines. Once DNase treatment has been initiated, it is usual to continue
to receive the treatment indefinitely, but a number of people do also stop taking treatment for various reasons.
Furthermore, in the IPW analysis, there were no extreme weights, suggesting that the assumption of positivity held.
Consistency concerns the definition of the intervention. The standard dosage and frequency of DNase is 2.5 mg once
a day, but a small number of patients receive a different dosage or frequency. Unfortunately, dosage data are not
routinely collected in the Registry. However, consistency is considered to hold under an intervention defined as
“receives DNase as prescribed by doctor'.
All models included the time‐varying covariates ppFEV1 and IV days as both outcomes and confounders. The
analyses also adjusted for baseline confounders: age, sex, ethnicity, and genotype class (a binary marker of the severity
of the CF‐causing mutation). It is possible that there is residual confounding of the treatment‐outcome association and
there were a number of other covariates measured in the UK CF Registry that could have been adjusted for, eg, smoking
status or body mass index (BMI). However, there is a large amount of missing data in these variables, resulting in many
observations being dropped from the analyses if they were included. In sensitivity analyses based on the subset without
missing data adjusting for time‐varying smoking status and BMI had only a very small impact on the effect estimates.
Our analysis included 22 357 annual assessments from 3847 people. The median number of visits per person was 8
(IQR, 5‐9). DNase was used for at least 1 year by 2251 people (58.5%) and for at least 5 years by 823 people (21.4%).
Table 1 gives an overview of the people included in the analysis at baseline.
5.1 | Results of lung function analysis
Figure 10 presents the results of the estimated population‐average effect of DNase on ppFEV1 depending on length of
treatment use. At 1 year, all methods except g‐computation formula estimate that treatment has a negative effect on
ppFEV1. The results for SCMM, g‐computation formula, and g‐estimation are, however, not significant (P = .86, .89,
and .86, respectively), whereas IPW and HA‐MSM estimate a stronger, significant, negative effect (P < .001 and .005),
which does not change much upon truncation of the extreme weights. Looking at longer term effects, all methods
showed a trend with the treatment effect becoming more negative through time, with truncated IPW estimating the
largest difference in ppFEV1 between those taking and not taking treatment of −8.81% (95% CI, −10.50 to −7.12,
P < .001) and HA‐MSM the smallest effect of −1.52% (95% CI, −3.30 to 0.27, P = .097). Full results from this analysis
can be found in Table S7.
SCMM, and g‐estimation were also used to investigate effect modification of the treatment effect by time‐varying
ppFEV1. These results are presented in Figure 11 and show that treatment was estimated to be beneficial in people
with lower baselined ppFEV1. HA‐MSM estimated an intercept term of 3.32, with treatment becoming less beneficial
by 0.57 per 10% change in baseline ppFEV1. This equates to a beneficial effect for people with a baseline ppFEV1 below
58% and a negative effect for people with ppFEV1 above 58%. SCMM and g‐estimation estimated a more attenuated
interaction effect where treatment became less effective by 0.37 per 10% change in baseline ppFEV1. This means that
for these methods, treatment was estimated to be beneficial for people with a baseline ppFEV1 up to 73%.
Looking at the 5‐year treatment effect, the interaction between treatment and ppFEV1 was estimated to increase in
strength leading to a bigger differentiation in effect between those with low and high baseline ppFEV1. In the case of
HA‐MSM, the intercept was estimated to be 8.30 with a change in effect of −1.29 per 10% increase in ppFEV1, leading
to a boundary for a beneficial effect of 64%. G‐estimation showed a stronger interaction effect at 5 years of −2.69%, but
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due to the increased SE, this was not significant (P = .16). The full results from the analysis including the interaction
term can be seen in Table S8.
5.2 | Results of IV days analysis
Similarly to the ppFEV1 analysis, we generally estimated a negative effect when considering the population average
effect of DNase on the annual number of IV days. These results are shown in Figure 12 and can also be seen in more
detail in Table S9.
At 1 year, all methods estimated a strong, significant decrease in the odds of having zero IV days and an increase in
the overall rate of the number of IV days for those receiving treatment. As we observed in the simulation studies, the
estimates from g‐estimation were larger due to the fact that it does not estimate the odds of a zero count separately
to the overall rate.
TABLE 1 Descriptive baseline statistics of people included in data analysis. Mean (SD) are given for continuous variables and n (%) for
categorical variables
Variable
Received DNase During Follow‐Up?
No (n = 1596) Yes (n = 2251)
Age, y 20.8 (13.9) 16.0 (11.7)
ppFEV1 84.5 (19.9) 78.6 (20.5)
Annual IV days 5.8 (14.4) 10.6 (19.4)
Sex
Female 716 (44.9) 1081 (48.0)
Male 880 (55.1) 1170 (52.0)
Ethnicity
Caucasian 1547 (96.9) 2172 (96.5)
Other 49 (3.1) 79 (3.5)
Genotype class
High 909 (57.0) 1708 (75.9)
Low 310 (19.4) 183 (8.1)
Unassigned 377 (23.6) 360 (16.0)
G−Estimation
G−Formula
SCMM
HA−MSM (truncated)
HA−MSM
IPW of MSM (truncated)
IPW of MSM
1.0e+300−1.0e+300−6 −4 −2 0 2
Difference at 1 Year
−6 −4 −2 0 2
Difference at 2 Years
−8 −6 −4 −2 0 2
Difference at 3 Years
−10 −8 −6 −4 −2 0 2
Difference at 4 Years
−10 −8 −6 −4 −2 0 2
Difference at 5 Years
Change in ppFEV1
FIGURE 10 Plots showing the estimated population‐average effect of DNase treatment on ppFEV1. HA‐MSM, history‐adjusted marginal
structural models; IPW, inverse probability weighting; MSM, marginal structural models; SCMM, sequential conditional mean models
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The estimates for the 4‐year treatment effects were very similar to the 1‐year treatment effect estimates, so although
treatment was still not estimated to be beneficial, we did not observe a trend of divergence between the treated and
nontreated as was observed with ppFEV1.
The results including an interaction term between previous number of IV days and treatment are shown in
Figure 13. In people who had previously had zero IV days, treatment was estimated to decrease their odds of zero future
IV days by between 0.62 (HA‐MSM) and 0.73 (SCMM), but for every 10 additional previous IV days, the odds of zero
future IV days increased by between 1.16 (HA‐MSM) and 1.17 (truncated HA‐MSM). This means that treatment would
be estimated to become beneficial on the odds of zero future IV days in individuals who previously had more than
between 21 IV days (SCMM) or 32 IV days (HA‐MSM).
Considering the overall rate of IV days, the interaction effect was not significant for HA‐MSM but was for SCMM
and g‐estimation, where for people with zero previous IV days, treatment was estimated to increase the rate of future
IV days by between 1.12 (SCMM) and 1.36 (g‐estimation), and this was estimated to decrease by a rate of 0.98 (SCMM)
and 0.94 (g‐estimation) per 10 IV days, resulting in a treatment estimated to be beneficial for people with more than 56
previous IV days for SCMM or more than 50 previous IV days (g‐estimation).
By 4 years, the interaction present at 1 year modifying the effect of the odds of a zero count had attenuated from 1.16
to 1.08 and was no longer significant. However, there was moderate evidence of interaction when considering the
overall rate of IV days with treatment estimated to be beneficial at 4 years in those who had previously had more than
43 days (HA‐MSM) or 162 IV days (g‐estimation). Table S10 contains the full results from this analysis.
6 | DISCUSSION
We have investigated the suitability of five methods for estimating treatment effects in longitudinal observational data
using simulation studies and applied the methods to the UK CF Registry. The focus was on five features encountered in
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FIGURE 11 Plots showing the estimated effect of DNase treatment on ppFEV1 with effect modification by previous measure of ppFEV1.
The intercept term is the estimated effect for an individual with ppFEV1 equal to 0 in the previous year, and the interaction effect is the
estimated change per 10 increase in the previous year's ppFEV1. HA‐MSM, history‐adjusted marginal structural models; SCMM, sequential
conditional mean models
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these investigations (Section 2.2). The suitability and performance of the methods differs depending on the research
question, the nature of the treatment effect of interest, and the features of the data. Here, we provide an overview
and recommendations based on our findings.
Our simulation studies showed that all the methods we considered are suitable for analysing registry data to inves-
tigate treatment effects in many scenarios. Specifically in the standard scenario, where all models are correctly specified,
all methods performed very similarly with little impact depending on the method chosen.
In the case of IPW, however, there were noticeable differences between the method with truncated and untruncated
weights. In most situations, the untruncated weights performed best, but in the situation of causal pathways being
misspecified, the truncated weights showed much better performance. In a real scenario, we would not know which
scenario we are in; it would therefore be difficult to know when weights should be truncated or not. It may be sensible
to only truncate when there are “extreme” weights, but there is no clear definition of how large a weight must be before
it is “extreme.” This would suggest, therefore, in situations where there is uncertainty in the correct direction of causal
pathways, that IPW not be used.
HA‐MSM performed similarly to IPW of MSM in cases where there is no effect modification, but as it is a more com-
plex method, it would be preferable to use standard IPW of MSM over HA‐MSM in most cases.
For measuring the 1‐year effect of treatment, SCMM would probably be the preferred method due to its good
performance in the simulation studies and its simplicity to implement. The obvious drawback is that the method cannot
be used to estimate long‐term effects like the other methods, but we recommend that this method be used alongside
other methods to check whether the more complex methods are in agreement with the 1‐year effect estimate of the
SCMM. In cases where the 1‐year effect estimate is markedly different between SCMM and another method, this could
act as a flag of potential issues with the analysis.
Another benefit of SCMM is that the model‐based standard errors will be approximately correct when the propensity
score is well estimated, meaning that the bootstrap does not need to be used and results can be obtained much faster
than using the other methods presented in this paper. The asymptotic SEs have been derived for IPW of MSM, but only
G−Formula
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FIGURE 12 Plots showing the estimated population‐average effect of DNase treatment on annual IV days. HA‐MSM, history‐adjusted
marginal structural models; IPW, inverse probability weighting; MSM, marginal structural models; SCMM, sequential conditional mean
models
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in a time‐fixed setting,26 and the difficulty of deriving these in a longitudinal setting necessitate the use of the bootstrap
for all the methods other than SCMM.
G‐computation formula tended to perform as well as other methods, only performing poorly where other methods
also performed poorly. The SE were consistently smaller than for other methods, which would always be preferable in
cases where we are confident in the specified models for the time‐varying covariates. However, in cases where there is
SCMM
HA−MSM (truncated)
HA−MSM
.6 .8 1 1.2
OR at 1 Year
.6 .8 1 1.2
OR at 2 Years
.6 .8 1 1.2
OR at 3 Years
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Odds of Zero IV Days − Intercept Term
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HA−MSM (truncated)
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OR at 1 Year
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.8 1 1.2
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.8 1 1.2
OR at 4 Years
Odds of Zero IV Days − Interaction Term
G−Estimation
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HA−MSM
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j
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G−Estimation
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HA−MSM (truncated)
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.9 .95 1
RR at 1 Year
.9 .95 1
RR at 2 Years
.9 .95 1
RR at 3 Years
.9 .95 1
RR at 4 Years
Rate of IV Days − Interaction Term
FIGURE 13 Plots showing the estimated effect of DNase treatment on IV days with effect modification by previous number of IV days.
The intercept term is the estimated effect for an individual with 0 IV days in the previous year, and the interaction effect is the estimated
change per 10 increase in the number of IV days in the previous year. HA‐MSM, history‐adjusted marginal structural models; SCMM,
sequential conditional mean models
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misspecification, the SE remains small, and with real data, it is unlikely that all the assumptions necessary for
g‐computation formula would be completely correct, which could result in tight confidence intervals around an incor-
rect effect estimate. In our scenarios, we did not encounter any issue with the g‐null paradox. This is because, for the
g‐null paradox to arise it is necessary for treatment to affect a time‐dependent confounder without having any direct
or indirect effect on the outcome.27 In our “no effect scenario,” treatment had no effect on either lung function or IV
days, which are acting as both the outcome and the time‐dependent confounders.
For continuous outcomes, g‐estimation performed well with the SE generally lying between those of g‐computation
formula and IPW, with the advantage that the method can also estimate effect modification by time‐varying covariates,
without the drawbacks of unstable weights which were sometimes observed in HA‐MSM. However, with the count out-
come, g‐estimation used a gamma model rather than the zero‐inflated negative binomial model like the other methods
presented in this paper. This resulted in only one rate ratio compared with the two distinct effect estimates of the other
methods making comparison difficult. In situations where the count outcome is not as skewed as the annual IV days in
the UK CF registry data, g‐estimation may be a suitable method, but in our setting, the other methods were generally
preferable.
We outlined how all methods can handle a count outcome, with the outcome model being restricted to a gamma
model in g‐estimation. A further complexity of the count outcome is the issue of non‐collapsibility. In the simulations,
we found that when there is truly no treatment effect, both marginal and conditional estimates were correctly consistent
with there being no treatment effect. However, in cases where there is a treatment effect, comparison between marginal
and conditional estimates from different methods is not as useful.
In addition to the five methods considered in this paper, there are other methods that could have been considered
for estimation of treatment effects in the analysis of the Registry data. One such method is targeted maximum likelihood
estimation, which is related to the g‐computation formula.28 This method has previously been compared with both IPW
and the g‐computation formula.29-31
Considering the analysis of the UK CF Registry data, as hypothesised, there did appear to be effect modification of
the treatment effect by previous ppFEV1 and previous annual IV days. This resulted in the population average esti-
mates hiding the fact that treatment could be beneficial for a group of people. Therefore, in this situation, we would
prefer to use SCMM, HA‐MSM, or g‐estimation, which can estimate effect modification of the treatment effect by
time‐varying covariates. Due to the fact that we are unsure of the correct specification of some of the causal path-
ways, HA‐MSM may not be a suitable method as shown in the simulation studies. However, the results from all four
methods (Figure 11) were very similar, suggesting that the direction of the causal pathways may not be misspecified
and any of the methods may in fact be suitable.
There was also evidence of effect modification of the treatment effect on the annual number of IV days. However,
depending on the method used, treatment was not estimated to become beneficial until individuals had had over at least
21 IV days in the previous year. In our data, almost 80% of people had fewer than 21 IV days, meaning treatment would
only be beneficial in reducing IV days in a small subset of people if these results are reliable. However, a further issue
with the annual IV days is that people are not only prescribed IVs as a result of an exacerbation of symptoms, but some-
times they are prescribed as a protective measure to avoid a future exacerbation. It is plausible that people who are more
likely to be prescribed treatment are also more likely to be prescribed IVs and it may not be possible to account for this
confounding with the available data in the Registry. The issue of unmeasured confounding has not been considered in
this paper, because it is an assumption of all the considered methods that there is no unmeasured confounding, but it is
important to remember this when considering if the data available are suitable for the desired analysis.
Previous work using more traditional statistical methods has only investigated the effects of up to 2 years of DNase
treatment. We have shown in this paper how the data available in registries can be harnessed with appropriate statis-
tical methods to investigate the effects of longer term use of treatments. Many treatments for CF would actually be used
for more than 5 years, which was the maximum time‐frame considered in this paper due to the limited sample size with
follow‐up longer than 5 years, but as more data are collected in the UK CF Registry, further analyses with longer follow‐
up could be performed.
Unfortunately, as with a lot of observational data, there are high levels of missingness in some of the variables
collected in the UK CF Registry. As missing data were not the focus of this paper, we presented the results of the data
analysis with adjustment for variables that are considered to be the strongest confounders affecting the probability of
receiving treatment and outcomes, as these variables are also more widely collected. Furthermore, sensitivity analyses
suggested that including other potential confounders such as smoking status or BMI did not result in significant changes
to the results.
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In conclusion, in most settings, more than one of the available methods would be suitable for the types of analysis
considered in this paper. In many cases, therefore, it may be beneficial to consider using more than one available
method, to see if the results are consistent. Of course, in cases where 2 separate methods give the same effect estimate,
this does not mean it is correct, but does add some reliability to the results. In cases where the methods gave very
different effect estimates, this would act as a flag to re‐examine the data, the assumptions of the methods, and the
suitability of the analyses performed.
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